RCM
ACOR

RA Capital Management’s Acorda Therapeutics ACOR Stock Holding History

RA Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-7,502
Closed -$21.3M – 32
2017
Q3 		$21.3M Hold
7,502
– – 1.92% 15
2017
Q2 		$17.7M Buy
7,502
+3,420
+84% +$6.78M 2.04% 16
2017
Q1 		$10.3M Buy
+4,082
New +$11.7M 1.26% 13
2016
Q2 		– Sell
-4,151
Closed -$13.2M – 39
2016
Q1 		$13.2M Buy
+4,151
New +$17.2M 1.68% 18

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RA Capital Management's ACOR Position: Q4 2017 in Review

RA Capital Management sold out of Acorda Therapeutics (ACOR) in Q4 2017, closing a stake of 7,502 shares — an estimated $21.3M sold.

RA Capital Management first reported a position in ACOR in Q1 2016 and held it in 4 quarters. The position peaked at $21.3M in Q3 2017. 150 funds tracked by Wall St. Rank hold ACOR as of Q4 2017.

  • RA Capital Management reported no remaining Acorda Therapeutics position as of Q4 2017 after selling out during the quarter.
  • RA Capital Management sold 7,502 Acorda Therapeutics shares in Q4 2017, an estimated $21.3M.
  • RA Capital Management first reported a position in Acorda Therapeutics in Q1 2016 and held it in 4 quarters.
  • RA Capital Management's Acorda Therapeutics position peaked at $21.3M in Q3 2017.
  • 150 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2017.

Based on RA Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.